Cybin Inc.

Acquisition of largest Phase 1 DMT study conducted to date is expected to accelerate CYB004 program timeline by nine months — — Phase 1 study evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and will inform clinical ... [Read]

TORONTO — Cybin Inc. (NYSEAMERICAN:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced the team of 28 esteemed faculty and advisors who will lead the Company’s EMBARK ... [Read]